Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

Pardanani, Animesh; Harrison, Claire; E. Cortes, Jörge; Cervantes, Francisco; A. Mesa, Ruben; Milligan, Donald; Masszi, Tamás; Mishchenko, Elena; Jourdan, Éric; M. Vannucchi, Alessandro; W. Drummond, Mark; Jurgutis, Mindaugas; Kuliczkowski, Kazimierz; Gheorghita, Emanuil; Passamonti, Francesco; Neumann, Frank; Patki, Abhay; Gao, Guozhi; Tefferi, Ayalew

doi:10.1001/jamaoncol.2015.1590

Public

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

Published in JAMA Oncology • Jun 18, 2015

Authors:

Animesh Pardanani

Claire Harrison

Jörge E. Cortes

Abstract

IMPORTANCE: Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival. Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF in ...

Subject

Medicine

Myelofibrosis

Constitutional symptoms

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!